BioNTech shuts three German plants, pivots to oncology amid losses

BioNTech, which profited heavily from its COVID-19 vaccine, is closing three factories in Germany due to financial losses. The company is refocusing its operations on oncology, signaling a strategic shift away from pandemic-era products. This move reflects the post-pandemic decline in vaccine demand and the company's need to adapt to a new market reality.